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Background {#sec005}
==========

HIV/AIDS has significantly impacted the health of children globally since the beginning of the pandemic \[[@pone.0234717.ref001]\]. There are about 1.7 million children aged 14 years and below living with HIV worldwide in 2018, and about 54% of them are receiving lifesaving antiretroviral treatment (ART) \[[@pone.0234717.ref002]\]. In 2018, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that they were 140,000 children living with HIV in Nigeria \[[@pone.0234717.ref003]\]. However, compared with global achievements, there have been relatively slower progress in Nigeria with only 35% of HIV infected children receiving ART in 2018 \[[@pone.0234717.ref003]\].

Government of Nigeria (GON) first commenced the national HIV treatment program in 2002, and with support from the United States (US) government through US President's Emergency Plan for AIDS Relief (PEPFAR) has significantly expanded HIV care and treatment services in the country \[[@pone.0234717.ref004]--[@pone.0234717.ref006]\]. The initiation of people living with HIV (PLHIV) on ART in Nigeria was initially restricted to tertiary health centers due to weak health systems in other levels of care. In 2004, following rapid scale-up of ART services and infrastructural upgrades, secondary hospitals began providing ART services to children in Nigeria. However, pediatric HIV treatment coverage in Nigeria lags behind adult HIV treatment coverage \[[@pone.0234717.ref007]\]. To improve treatment coverage in children, GON adopted the use of family index testing as a key strategy for improving case finding in its accelerated plan for scaling up access to pediatric HIV treatment services between 2016 and 2018 \[[@pone.0234717.ref008]\]. However, progress with implementation has been slow. A trend analysis of national data indicated that pediatric ART coverage (based on CD4 cell count eligibility criterion of \<350cells/μL) from 2010--2014 improved marginally from 10.2% to 20.7% while the adult ART program reached nearly half of all adults requiring ART in 2014 \[[@pone.0234717.ref007]\]. The UNAIDS 2018 estimates showed a disproportionately lower treatment coverage in children aged 0--14 years (35%) and in adult males aged 15 years and over (37%) compared with adult females aged 15 years and older (68%) \[[@pone.0234717.ref003]\]. Major reasons for the disproportionately lower coverage among children include among others, lower HIV testing positivity rates, indicating poorly-targeted HIV testing, and lower linkage to treatment among children.

In 2016, PEPFAR adopted a program strategy geared towards working with GON and other partners to refocus efforts in a small number of prioritized high--burden Local Government Areas (LGAs), designated as "scale-up LGAs", to achieve HIV epidemic control by the end of the fiscal year 2018 (FY18). This is in line with the ambitious UNAIDS 90-90-90 targets of having 90 percent of PLHIV diagnosed, 90 percent of those diagnosed on ART, and 90 percent of those on ART virally suppressed by 2020. Achieving these targets also demands dramatic progress in closing the treatment gap for children \[[@pone.0234717.ref009]\], and this requires finding children living with HIV as a first step.

A blanket approach to HIV testing has not worked well for pediatric HIV case identification in HIV programs in Africa \[[@pone.0234717.ref010]--[@pone.0234717.ref012]\]. In Nigeria, blanket testing has not worked even in high-burden LGAs. As of June 2016, program monitoring results from PEPFAR-supported facilities in scale-up LGAs showed an overall HIV-positivity rate of 1.1% for children aged 0--14 years. The overall HIV-positivity rate for children and adolescents aged 0--19 years tested between October 2015 and September 2016 at all PEPFAR--supported LGAs was 0.8% with a 71% linkage to treatment rate for those who tested positive during this period. However, published reports from similar setting suggests that a more targeted approach to test may improve testing yield \[[@pone.0234717.ref013]\]. These statistics are indicative of a need for more effective targeted testing strategies in order to improve testing efficiency, by increasing testing yield, and efficacy, by linking more HIV-positive children to care and treatment.

To address the issues of low HIV testing yield and linkage among children, we piloted a pediatric intensive case-finding (PICF) approach at selected health facilities in Nigeria to identify efficient HIV testing points to identify children living with HIV for early ART initiation and to develop effective strategies for scale-up of pediatric HIV case finding and linkage in Nigeria.

Methods {#sec006}
=======

Study design {#sec007}
------------

This is a retrospective analysis of available program data collected during a PICF pilot in Nigeria.

Study population {#sec008}
----------------

Data from all children aged less than 15 years seeking care in selected points of service (POS) in selected secondary level hospitals during the PICF pilot were included in the analysis.

The major outcome measures {#sec009}
--------------------------

The HIV positivity rate among children tested, linkage rate to treatment among children tested positive, HIV results by age group and point of services, the proportion of total positive by point of service, and predictors of HIV positive result among children tested in pilot sites were the main outcome measures. Patients factors included in the model for odds ratio were age group and HIV testing point of service.

Description of sites and process of site selection for pilot {#sec010}
------------------------------------------------------------

In October 2016, a pediatric program gap analysis was conducted across ART sites in Nigeria by comparing the proportion of HIV positive children on ART with those of adults on ART. The review team looked at the total clients on ART at each site to determine the ratio of children \<15 on ART compared to that of adults currently on ART. It was expected that 6% of individuals on ART within each facility should be \<15 years, based on the national proportion of children living with HIV among all PLHIV at the time of review (220,000 of 3,400,000 total estimated PLHIV) \[[@pone.0234717.ref014]\]. The pediatric ART gap for each site was calculated by estimating the additional number of children needed to be put on ART to make the ratio up to 6% of total clients currently on ART. The PICF pilot was conducted from November 15, 2016, to March 31, 2017, in selected treatment sites supported by PEPFAR in Nigeria. The selection was guided by the pediatric HIV program gap analysis. Nine secondary level hospitals with the widest gap were selected from the over four hundred treatment sites supported by PEPFAR to participate in the pilot.

Strategies implemented during PICF pilot {#sec011}
----------------------------------------

Strategies for improving pediatric HIV case identification were implemented at all points of service (POS) for pediatric care seekers at the nine selected hospitals between November 15, 2016, to March 31, 2017. The POS were family index testing, pediatric outpatient department (POPD), tuberculosis (TB) clinics, immunization clinics, and pediatric inpatient ward. The family index testing POS identified new cases through a previously identified case, i.e. children of an HIV positive mother or siblings of an index child. HIV positive mothers were identified during counseling, at the ART clinic, ante-natal clinic, post-natal clinic or outpatient clinics and encouraged to return to the clinic with their children for HIV test. Additionally, parents of a previously identified HIV positive child were also encouraged to bring other children with unknown HIV status for HIV tests. At the TB clinic and pediatric inpatient ward, HIV testing was offered to all children whose parents reported that the child's HIV status was unknown. Targeted testing in immunization clinics was introduced, based on maternal HIV status; specifically, only infants whose mothers had unknown HIV status or were previously identified as HIV positive were eligible for testing. Finally, at the POPD children were screened to determine their eligibility for an HIV test using the Bandason screening tool \[[@pone.0234717.ref012]\].The Bandason screening tool consists of four questions \[[@pone.0234717.ref012]\]: "Has the child been admitted before?" "Does the child have recurring skin problems?" "Are one or both parents of the child deceased?" and "Has the child had poor health in the last 3 months?" An answer of yes to any of the four screening questions made the child eligible for an HIV test. The health workers at the selected sites were trained on the use of the Bandason screening tool. Advocacy about the PICF pilot was conducted to the leadership and staff of the selected sites and to the host state and local governments where these sites were located. These PICF strategies were piloted at the TB clinics, pediatric inpatient medical wards, adult outpatient clinics among families of identified index cases, POPDs, and the immunization clinics in the selected sites. All children less than 18 months of age were tested using HIV DNA PCR while children greater than 18 months of age were tested using a rapid diagnostic test, in accordance with World Health Organization testing guidelines \[[@pone.0234717.ref015]\]. The strategy for improving the linkage of newly-diagnosed to ART initiation was accompanied, immediate referral using volunteers to the ART clinic.

Data analysis {#sec012}
-------------

The proportions of children tested and testing HIV positive were analyzed by age group, and percent contributions of each age group to total testing and total identified HIV-positive children were reported with 95% confidence intervals (CI). The proportions of children tested and testing HIV positive were then analyzed by POS. Additionally, the HIV-positivity rates from family index testing, POPD, inpatient ward, and TB clinics at pilot hospitals were reported with 95% CIs. To examine testing efficiency at the POS, we compared the contribution of each POS to the total children tested and total identified HIV-positive children at the sites. To determine the linkage rate, we compared the number of children testing HIV positive at the POS of interest, with the number of HIV-positive children started on treatment from that POS. Furthermore, we calculated unadjusted and adjusted (adjusting for testing POS when comparing age group and for age group when comparing the testing POS) odds ratios for identification of pediatric HIV case by covariates of age group and POS. To account for the clustered design (i.e., design effect of the nine sites for combined analysis), we used a weighted analysis accounting for clustering by site. All analysis was done using Stata 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LP). We accounted for the complex survey design (i.e., clustering and weighting) using svyset and svy procedures in Stata during data analysis

Ethics statement {#sec013}
----------------

The study protocol was reviewed and approved by the National Health Research Ethics Committee of Nigeria (NHREC). The protocol received a non-research determination from the US Centers for Disease Control and Prevention (CDC) Atlanta. Patient informed consent was not required as only routine, anonymous, operational monitoring data were collected and analyzed.

Results {#sec014}
=======

HIV testing outputs from all POS by age group {#sec015}
---------------------------------------------

Information on outputs from the HIV testing service by age group from all POS from the nine pilot sites are summarized in [Table 1](#pone.0234717.t001){ref-type="table"}. A total of 6,747 children who visited the participating secondary level sites during the pilot period were enumerated. Overall, a total of 2,180 (32.3%) of the enumerated children had unknown HIV status. Of those with unknown HIV status, 2,021 (92.7%) had parents or guardians who consented to have them tested for HIV, and among those with consent provided, 1,822 (90.2%) were tested for HIV. Among those tested, 43 (2.4%) of the children were found to be HIV positive. Children in the age group 1 to 4 years contributed the largest proportion (41.3%, \[95% CI 39.0--43.6%\]) of the total number of children tested, followed by children in the age group 5 to 9 years (28.5%,\[26.5--30.7\]). Similarly, children in the age groups 1 to 4 years and 5 to 9 years contributed 44.2% (30.2--59.1%) and 27.9% (16.6--43.0%) of the total number of children that tested HIV positive. Of note, all 43 HIV-positive children identified were linked to ART initiation.

10.1371/journal.pone.0234717.t001

###### HIV testing pediatric cascade by age group across all PICF pilot sites.

![](pone.0234717.t001){#pone.0234717.t001g}

  Indicator                                                                                         Age Group in Years                                                                  
  ------------------------------------------------------------------------------------------------- -------------------- -------------------- -------------------- -------------------- -----------------
  **Number children enumerated (N)**                                                                3,164                1,400                1,254                929                  6,747
  **Number children with Unknown HIV status and eligible for HIV test (n \[col %\])**               382 (12.1%)          851 (60.8%)          575 (45.9%)          372 (40.0%)          2,180 (32.3%)
  **Number children with Unknown HIV status whose guardian consented for HIV test (n \[col %\])**   332 (86.9%)          833 (97.9%)          521 (90.6%)          335 (90.1%)          2,021 (92.7%)
  **\# Tested (n \[col %\])**                                                                       230 (69.3%)          752 (90.3%)          520 (99.8%)          320 (95.5%)          1,822 (90.2%)
  **\# Tested HIV+ (n \[col %\])**                                                                  4 (1.7%)             19 (2.5%)            12 (2.3%)            8 (2.5%)             43 (2.4%)
  **\# Initiated on ART (n \[col %\])**                                                             4 (100%)             19 (100%)            12 (100%)            8 (100%)             43 (100%)
  **Testing yield (%\[95%CI\])**                                                                    1.7% (0.7--4.6)      2.5% (1.6--3.9)      2.3% (1.3--4.0)      2.5% (1.3--4.9)      2.4% (1.8--3.2)
  **Age group percent contribution to total HIV testing (%\[95%CI\])**                              12.6% (11.2--14.2)   41.3% (39.0--43.6)   28.5% (26.5--30.7)   17.6% (15.9--19.4)   100%
  **Age group percent contribution to total HIV+**                                                  9.3% (3.5--22.3)     44.2% (30.2--59.1)   27.9% (16.6--43.0)   18.6% (9.6--33.0)    100%

HIV testing acceptance for all age groups by POS {#sec016}
------------------------------------------------

The results from the HIV testing service by POS for all age groups and all pilot sites are summarized in [Table 2](#pone.0234717.t002){ref-type="table"}. Of the 2,180 children with unknown HIV status seen at all POS, parents or guardians of 2,021 children (92.7%) accepted that their children be tested for HIV. In family index testing, 807 out of 890 parents (90.7%) gave consent for their children to be tested. Acceptance rates for HIV testing was 76.4%, 95.3%, 99.5% and 100% for immunization clinic, POPD, pediatric inpatient ward and TB clinic respectively.

10.1371/journal.pone.0234717.t002

###### HIV testing pediatric cascade by points of service across all PICF pilot sites.

![](pone.0234717.t002){#pone.0234717.t002g}

  Indicator                                                                                         Points of service                                                                                   
  ------------------------------------------------------------------------------------------------- -------------------- -------------------- ------------------ ----------------- -------------------- --------------------------------------------
  **Number children enumerated (N)**                                                                2,509                1,098                44                 2,835             257                  6,743[\*](#t002fn001){ref-type="table-fn"}
  **Number children with Unknown HIV status and eligible for HIV test (n \[col %\])**               890 (35.5%)          955 (87.0%)          15 (34.1%)         127 (4.5%)        193 (75.1%)          2,180 (32.3%)
  **Number children with Unknown HIV status whose guardian consented for HIV test (n \[col %\])**   807 (90.7%)          910 (95.3%)          15 (100%)          97 (76.4%)        192(99.5%)           2,021 (92.7%)
  **\# Tested (n \[col %\])**                                                                       693 (85.9%)          906 (99.6%)          15 (100%)          16 (16.0%)        192 (100%)           1,822 (90.2%)
  **\# Tested HIV+ (n \[col %\])**                                                                  24 (3.5%)            9 (1.0%)             1 (6.7%)           0 (0%)            9 (4.7%)             43 (2.4%)
  **\# Initiated on ART (n \[col %\])**                                                             24 (100%)            9 (100%)             1 (100%)           0 (0%)            9 (100%)             43 (100%)
  **Testing yield (%\[95%CI\])**                                                                    3.5% (2.3--5.1)      1.0% (0.5--1.9)      6.7% (0.9--35.2)   0 (0%)            4.7% (2.5--8.8)      2.4% (1.8--3.2)
  **Point of service percent contribution to total HIV testing (%\[95%CI\])**                       38.0% (35.8--40.3)   49.7% (47.4--52.0)   0.8% (0.27--3.1)   0.9% (0.5--1.4)   10.5% (9.2--12.0)    100%
  **Point of service percent contribution to total HIV+ (%\[95%CI\])**                              55.8% (40.9--69.8)   20.9% (11.3--35.6)   2.3% (0.3--14.8)   0 (0%)            20.9% (11.3--35.6)   100%

\*Four patients enumerated in malnutrition clinic but not tested were not included in the table

HIV testing outputs from all sites by POS {#sec017}
-----------------------------------------

HIV positivity rates by point of service were TB clinic = 6.7% (95% Confidence Interval (CI): 0.9--35.2%); pediatric inpatient ward = 4.7% (95%CI: 2.5--8.8%); family index testing = 3.5% (95%CI: 2.3--5.1%); POPD = 1.0% (95%CI: 0.5--1.9%); and immunization clinic = 0%. The largest proportion of children tested were from the POPD (49.7% \[95%CI: 47.4--52.0%\]), followed by family index testing POS (38.0% \[35.8--40.3%\]). However, the largest proportion of the total number of HIV-positive children identified were from the family index testing POS (55.8% \[95%CI: 40.9--69.8%\]), followed by POPD (20.9% \[95%CI: 11.3--35.6%\]) and the inpatient ward, accounting for 20.9% (95%CI: 11.3--35.6%) of the total number of children testing HIV positive. The TB clinic POS had the highest yield, at 6.7% (0.9--35.2%), but contributed only 2.3% (0.3--14.8%) of the total number of children testing HIV positive.

In examining odds ratios of pediatric HIV case detection by age group, after adjusting for POS, using age group \<1 year of age as the control, there was no significant difference in adjusted odds of HIV positivity rate by age group ([Table 3](#pone.0234717.t003){ref-type="table"}). However, in examining odds ratios of pediatric HIV case detection by POS, after adjusting for age, compared with the POPD, the inpatient ward (Adjusted Odds Ratio (AOR) 4.9 (95% CI: 1.9--12.8)) and family index testing POS (AOR: 3.7 (95% CI: 1.5--8.8)) had significantly higher odds for finding a HIV positive child ([Table 3](#pone.0234717.t003){ref-type="table"}). The AOR for TB clinic did not achieve statistical significance, but the magnitude of the effect was large and probably statistical significance was not achieved due to the small number of patients in the TB clinic.

10.1371/journal.pone.0234717.t003

###### Unadjusted and adjusted odds ratios of pediatric HIV case detection by patient age group and POS.

![](pone.0234717.t003){#pone.0234717.t003g}

  Patient Characteristics   Unadjusted Odds ratio (95%CI)   Adjusted Odds ratio (95%CI)
  ------------------------- ------------------------------- -----------------------------
  **Age group**                                             
  \<1 year                  1                               1
  1--4 years                1.5 (0.5--4.3)                  1.2 (0.3--4.1)
  5--9 years                1.3 (0.4--4.2)                  1.1 (0.3--4.3)
  10--14 years              1.4 (0.4--4.9)                  0.9 (0.2--4.4)
  **POS**                                                   
  POPD                      1                               1
  Family index              3.6 (1.7--7.7)                  3.7 (1.5--8.8)
  Inpatient ward            4.9 (1.9--12.5)                 4.9 (1.9--12.8)
  TB clinic                 7.1 (0.8--60.2)                 7.2 (0.9--60.9)

Discussion {#sec018}
==========

Our study found that the pediatric inpatient wards and family index testing POS provided the highest number of HIV-positive children, while still maintaining high HIV positivity rates compared with other POS. The pediatric inpatient ward and family index testing modality also contributed a disproportionately higher amount of total identified HIV-positive children than their contributions to the total HIV testing, a fact supported by significantly higher odds ratios of finding HIV-positive children in these POS compared with that of the POPD. While there were as many children living with HIV identified in the POPD as in the inpatient ward, this result was coupled with a significantly lower yield. Even with the use of the HIV risk screening tool in the POPD, this POS gave a low yield of 1.0%. TB clinics had the highest yield, but TB clinics had fewer absolute numbers of pediatric HIV cases found because there were few pediatric clients seen in that POS. These findings suggest that a focus on pediatric inpatient and family index testing POS as pediatric HIV testing points might be the most efficient approach for HIV testing among children in Nigeria.

The entry point for HIV testing in children influences the proportion of cases found \[[@pone.0234717.ref016]--[@pone.0234717.ref018]\]. A study by Wagner et al. conducted in Nairobi, Kenya, where HIV-infected adults were encouraged to bring their children for HIV testing (family index testing), found that the rate of pediatric HIV testing increased 3.8-fold from 3.5% to 13.6% \[[@pone.0234717.ref016]\]. A similar study by Lewis Kulzer et al. conducted in the Nyanza province in Kenya reported that HIV testing through the family index approach increased case detection among children\[[@pone.0234717.ref017]\]. Both study findings suggest that scaling up family index testing has the potential of improving HIV case detection among children. We also found that the family index testing modality was the most efficient POS for all sites, accounting for about 38% of total children tested but contributing more than half (55.8%) of all the positives identified.

One of the key recommendations of the national acceleration plan for improving pediatric case finding in Nigeria was the use of family index testing\[[@pone.0234717.ref008]\]. The findings from our study give credence to the recommended approach in the national acceleration plan. Furthermore, a study conducted in Cameroon that compared case detection in biological children of HIV-positive parents (targeted testing) and other children at the POPD (blanket testing), reported a higher HIV positivity rate of 3.5% in the targeted group compared with 1.6% in the blanket group\[[@pone.0234717.ref010]\].The HIV positivity rate of 3.5% among children identified through family index testing in our study was similar to the HIV-positive rate found in biological children of HIV-positive parents in the study in Cameroon\[[@pone.0234717.ref010]\].

Our study found a relatively high HIV positivity yield of 4.7% among children in the inpatient ward. A study conducted in Zambia among hospitalized children reported a high HIV positivity rate of 29.2% and concluded that the inpatient ward has a huge potential for identifying children with HIV\[[@pone.0234717.ref019]\]. The differences in HIV positivity rates in our study and the Zambian study was the population HIV prevalence. Whereas Nigeria's adult population HIV prevalence was 1.5% \[[@pone.0234717.ref014]\] that for Zambia was 11.3% \[[@pone.0234717.ref020]\]. Nonetheless, there was a consistently high HIV case finding among children in the inpatient ward in both studies.

PEPFAR program guidance suggests that testing children not only in pediatric wards, and but also in POPDs among children screening as high risk may increase the case detection of HIV-infected children \[[@pone.0234717.ref021]\]. Our findings suggest that the pediatric inpatient ward was an efficient POS for finding children living with HIV. Although the contribution of inpatient (20.9%) to case finding was similar to POPD (20.9%), a lot more tests had to be done at POPD to find the same number of patients as the inpatient ward. The observed HIV positivity yield of 1% at POPD in our study using the Bandason tool was much lower than the reported HIV positivity yield of 4% at POPD by Yumo et al using a symptoms-based testing strategy in Cameroon \[[@pone.0234717.ref010]\]. The differences in HIV positivity rates were due to differences in general population HIV prevalence, the adult HIV prevalence in Cameroon is much higher, 3.6% compared with 1.5% in Nigeria \[[@pone.0234717.ref003], [@pone.0234717.ref022], [@pone.0234717.ref023]\]. In both studies, the HIV test results at POPD was similar to the population HIV prevalence. However, considering the relatively large number of children that needed to be tested to find a positive case at the POPD despite the use of a screening tool in our study, there is a need to re-assess the validity of the Bandason screening tool in low HIV prevalence settings like Nigeria and among children, less than six years since the Bandason tool was only tested for children above six years \[[@pone.0234717.ref012]\].

Additionally, we found the highest HIV positivity rate (6.7%) and the highest adjusted odds ratio for finding a positive result among children at the TB clinic. In a much larger study among children infected with TB conducted by Tilahun et al in Ethiopia, 291 children were tested for HIV and 28.2% of them were HIV positive \[[@pone.0234717.ref024]\]. Our findings suggest all children in TB clinic should be tested for HIV, but TB clinic cannot be counted on to provide high absolute numbers of children living with HIV

In our study we observed that all the children identified through the POS were also initiated on treatment, giving a linkage to treatment rate of 100%. The sites employed a strategy of accompanied referral, which used volunteers to immediately accompany parents or guardians and newly diagnosed children to ART POS to ensure all children identified HIV positive were linked to treatment. The approach assisted parents/guardians to quickly navigate the ART clinic and obtain care for their children. The excellent linkage rate observed in our study was comparable to those reported for a South African ART program that utilized escort services to facilitate linkage to treatment among HIV positive adults, and scale-up of this approach in the Nigeria HIV program will ensure that identified HIV-positive children are offered ART \[[@pone.0234717.ref025]\].

We found HIV testing acceptance rates of 76.4%, 90.7%, 95.3%, 99.5% and 100% for parents/guardians at immunization clinic, family index testing, POPD, inpatient ward and TB clinic respectively. A systematic review of several studies conducted mainly in Kenya and Uganda by Govindasamy et al reported the highest acceptance of HIV testing (86.3%) by parents/guardians at inpatient wards and lowest acceptance (51.7%) in the family index modality \[[@pone.0234717.ref026]\]. Compared with reports by Govindasamy et al, with the exception of the immunization clinic, our study found a much higher HIV testing acceptance rate among all the provider-initiated testing and counseling POS. The finding suggests that the pre-test counseling provided for families of at-risk pediatric patients at our study sites was effective. Furthermore, a study conducted in Cameroon by Yumo et al reported high HIV testing acceptance rates for children among both HIV-positive parents (99.7%) and other guardians/parents at POPD (98.8%). In our study, HIV acceptance rates were comparable to those reported by Yumo et al for Cameroon \[[@pone.0234717.ref010]\].

However, even with this high acceptance by guardians to have at-risk pediatric patients tested for HIV, we found that there were missed opportunities for testing at the immunization clinic and at the family index testing POS. We found that 76.4% of mothers accepted the HIV test for their babies but only 16.5% of children with unknown status at the immunization clinic were eventually tested for HIV. A systematic review examining HIV testing in immunization clinics in children reported an acceptance rate of 89.5 to 100%. However, in that systematic review, only about 56.8% to 86.0% of the children were eventually tested \[[@pone.0234717.ref027]\]. While the acceptance of HIV testing in the immunization clinic in our study was only slightly lower than that in the systematic review, the percentage of children tested at immunization clinics in our study was much lower than those previously reported. While previous studies have reported that immunization clinic may be a promising area for identifying and testing HIV exposed children in high HIV prevalence settings \[[@pone.0234717.ref028], [@pone.0234717.ref029]\],the low HIV positivity rate among children tested at the immunization clinics in our study suggests that scaling up testing at immunization clinic as it is currently done may not be an efficient way to find pediatric HIV cases.

There were also missed opportunities at the family index testing POS. About 24% of children with unknown status identified through the family index POS were not tested for HIV. However, the percentage of children with unknown status that was not tested (24%) in our study was much lower than the 43.3% reported by Yumo et al for neighboring Cameroon\[[@pone.0234717.ref030]\]. A major reason for the missed opportunity was that at this POS, the method for getting these children tested was simply to ask parents to return to the clinic with the children, and parents often did not return with their children for HIV testing as scheduled. A similar factor played a role in the high missed opportunity in the study in Cameroun \[[@pone.0234717.ref010]\]. The researchers insinuated that the reason for the high missed opportunity in their study was because parents initially came for their own care and did not have their children with them at the time of accepting to test their children and eventually failed to follow through \[[@pone.0234717.ref010]\]. Our study did not investigate the reasons for the failure of parents or guardians to return with their children. However, a previous study in Nigeria found that HIV infection among family income earners adversely affects families socioeconomically and impacts on parents' ability to continue to seek health services for their children, including for family index testing \[[@pone.0234717.ref028]\]. This suggests that a home-based HIV testing and counseling approach for children of consenting parents/guardian, or health outreach workers going to the home to conduct testing of children, may be required for the successful implementation of the family index testing.

In examining the pediatric HIV testing cascade by age group in our study, it is noteworthy that although the age group \<1 year had the most children accessing care, it also had the lowest proportion of children with unknown HIV status, and lowest percentage testing HIV positive. This may be because all sites involved in our study had a PMTCT program. Studies have demonstrated that PMTCT programs increase HIV test rates during ante-natal care in pregnant women, promote uptake of antiretroviral drugs during pregnancy and promote HIV testing among HIV exposed infants \[[@pone.0234717.ref031]--[@pone.0234717.ref034]\]. We found that the percentage of contributions by age group to total children tested were closely aligned to the proportions contributed to total HIV positive found. This finding was further supported by no statistically significant difference in odds ratios for finding an HIV-positive child by age group. Thus, our findings do not support program emphasis on a specific age group. That said, because of a greater proportion of children with an unknown HIV status among 1-4-year-olds, the largest number of HIV cases were found among this age group. This indicates the need for health providers to consider HIV risk stratification for all children irrespective of age if no HIV status is documented when they present at a health facility.

The strength of our study is the data from a large number of samples of children analyzed in the study. However, the purposive nature of site selection limits the generability of the findings from our analysis. Additionally, other POS with the potential to give high positivity yields, such as malnutrition clinics, were not thoroughly assessed in our study. Nonetheless, the findings provide important insights into how HIV positivity rates and testing efficiency can be improved by focusing on testing and ensuring linkage, in targeted POS in health facilities.

Conclusion {#sec019}
==========

The pilot of pediatric intensified case finding demonstrated that the family index testing POS, followed by pediatric inpatient testing, was the most efficient testing streams for HIV testing among children. Specifically, these modalities identified high numbers of children living with HIV while maintaining high HIV positivity rates. Furthermore, while the POPD was an important testing point for identifying high numbers of HIV positive children, yield was poor, even with the application of a validated screening tool for identifying children at risk for having HIV. Testing among children attending TB clinic gives high yield but low absolute numbers. The study findings suggested that to improve facility-based HIV positivity rates among children aged 0--14 years in Nigeria, an increased focus on offering and ensuring HIV testing through family index testing, offering testing to all children in pediatric inpatient wards who do not know status, testing in POPD only if targeted using a validated screening tool tailored to the population, and among all children attending TB clinics is appropriate. This focus, coupled with the continuation of the 100% linkage to ART initiation among these children in the study, will allow Nigeria to make progress in closing the pediatric ART treatment gap.

Supporting information {#sec020}
======================
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Feb 07 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.
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Academic Editor
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Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I deeply appreciated the opportunity to review this excellent work. It represents a great effort of the government of Nigeria to achieve the ambitious UNAIDS target of 90-90-90 by 2020. Table 3 is describing unadjusted and adjusted odd ratios of pediatric HIV case detection by patient age group and HIV positive results. However there is no p-value calculated for each variable (Age group and HIV positive results).

Reviewer \#2: This paper is about identifying an efficient case-finding approach for children with HIV and linking them to care in Nigeria. It was conducted well and tells a good story about where to focus HIV testing of children in large hospital settings in Nigeria for efficient case-finding. Table 2 is particularly illuminating, it is easy to see where to target testing based on this table.

Overall the information is sound, but can benefit from some re-structuring of information for consistency and flow, particularly in the results and discussion and overall to make sure the abstract mirrors the paper's findings and the methods, results, and discussion tie together well. See specific comments and suggestions below.

Abstract

Results are largely presented well, the results first provide a break down of the numbers test by age group, then by department, and then by positivity rate, in order of highest % to lowest.

Minor issue:

Results: In the number tested by age group 5-9 years=520 (28.5%) should follow the 1-4 year age group for consistency and flow.

Major issue:

Conclusion: Unclear why the recommendation ordering for focused testing is "pediatric inpatient wards, through family testing, and perhaps TB clinic is appropriate". It is not based on positivity alone, therefore authors should indicate why those modalities (similar to manuscript conclusion)

Background,page 4

Minor issue:

There is redundancy in the last few sentences of the last paragraph, suggest streamlining.

Methods

Study design, page 4

Minor issue:

Suggest adding retrospective to the design.

Study population, page 4

Minor issue:

Regional information missing. Rural, urban, semi-urban?

Outcomes measures, page 4

Major issues:

Incomplete, what about number and proportion tested and positive in each department?

For factors associated, give examples (i.e. testing acceptance)

Description and process of site selection for pilot, page 4

Minor issues:

Suggest starting with the first research activity done, for instance if the gap analysis was first, start there and flow forward to details of determining children ration.

Cite (220,000/3,400,000 estimated PLHIV)...

Strategies, page 4

Nice overall description of strategies and process to roll out.

Minor issues:

Consider adding when strategies were implemented to the first sentence

What department(s) was family testing conducted in?

Data Analysis, page 5

Major issue

Section on data collection

In the Analysis section, suggest putting the sentence about STATA at the end

Results

Major issues -- editing and additional information

HIV Testing Outputs from all sites by POS by age group, page 6

Linkage mention seems out of place in this paragraph, consider its own paragraph and placing it with HIV testing cascade flow.

HIV Testing Outputs from all sites by POS, page 6

This text draws from Table 2, which is a nicely presented table of findings. The extra details on the family testing may not be essential here, so evident in the table and other departments are not presented similarly.

Some redundancy of results mid-paragraph. Suggest refining and keeping any interpretation to Discussion.

Suggest that the results include a paragraph summarizes testing acceptance (based on Table 2), since it is discussed in the Discussion.

Discussion, page 7

Major issues - Some rewriting and reorganization is warranted:

Important points are captured here but suggested restructuring for better flow and presentation. For instance, first primary findings, then supporting / conflicting evidence, other findings, and limitations.

Ordering suggestions

Paragraph 1 - Suggest starting with overall primary findings that answers research question

Paragraph 2 -- Suggest moving this further down since not about primary findings. Suggest adding references to support ideas here.

Paragraph 3 -- Suggest move this paragraph up since it supports primary findings. Any references to substantiate findings on inpatient care? For TB consider adding information to validate Conclusion statement.

Paragraph 4 -- Suggest keeping it after the above paragraph since tied to primary findings.

Paragraph 5 -- fine, no comments

Paragraph 6 -- Systematic review on acceptance, interesting but need to mention acceptance in results Suggest starting with what the study found (to put it in context), then introduce the systematic review and corroborating findings

Paragraph 7 -- fine, no comments

Paragraph 8 -- PEPFAR/inpatient ward-- suggest weaving into primary findings, since it is provides support for inpatient findings.

Paragraph 9 -- fine, no comments

Conclusion

Question about this sentence: "Specifically, these modalities identified high numbers of children living with HIV while maintaining high yields"

isn't identifying high numbers of children living with HIV yield? Please clarify.

Reviewer \#3: Based on presented data, some conclusions are not drawn appropriately. This issue is more pronounced in the discussion section. Please, see the review attachment for our comments in the different sections of the manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Habakkuk A. Yumo

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: manuscript review, pediatric HIV case finding Nigeria.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234717.r002

Author response to Decision Letter 0

6 Feb 2020

Response to Reviewers' Comments

Reviewer 1 Comments and Authors' responses:

Reviewer \#1: I deeply appreciated the opportunity to review this excellent work. It represents a great effort of the government of Nigeria to achieve the ambitious UNAIDS target of 90-90-90 by 2020. Table 3 is describing unadjusted and adjusted odd ratios of pediatric HIV case detection by patient age group and HIV positive results. However, there is no p-value calculated for each variable (Age group and HIV positive results).

Authors' response:

We did not include the p values for the values as rightly observed by reviewer. However, we provided the 95% Confidence Intervals (CIs) for all the values presented. The determination statistical significance or Non-significance can be accurately made by using the 95% CIs\[1\].

Reviewer 2 Comments and Authors' responses:

Overall the information is sound, but can benefit from some re-structuring of information for consistency and flow, particularly in the results and discussion and overall to make sure the abstract mirrors the paper's findings and the methods, results, and discussion tie together well. See specific comments and suggestions below.

Authors' response:

We have re-structured information in both the abstract, results and discussions to improve the flow and consistency throughout the manuscript. The information in the abstract also mirrors the content of the paper.

Abstract

Results are largely presented well, the results first provide a break down of the numbers test by age group, then by department, and then by positivity rate, in order of highest % to lowest.

Authors' response:

We have now included reorganized the order of presentation of results by age group to improve the flow. Please see lines page 1, 29 to 31 of marked up version of revised manuscript.

Minor issue:

Results: In the number tested by age group 5-9 years=520 (28.5%) should follow the 1-4 year age group for consistency and flow.

Authors' response:

Authors agree with reviewer's suggestions. We have now included reorganized the order of presentation of results by age group to improve the flow. Please see page 1, lines 29 to 31 of marked up version of revised manuscript.

Major issue:

Conclusion: Unclear why the recommendation ordering for focused testing is "pediatric inpatient wards, through family testing, and perhaps TB clinic is appropriate". It is not based on positivity alone, therefore authors should indicate why those modalities (similar to manuscript conclusion)

Authors' response:

The POPD was not an efficient point of service: low yield, and two other points of service here (peds inpatient, and family index) had statistically significant odds ratio (OR) of finding HIV+ child than POPD. We mention TB clinic as "perhaps" because the OR did not reach statistical significance, but magnitude of effect was large and probably statistical significance was not achieved due to small number in TB clinic. Inclusion of POPD would seem to muddy these findings, not clarify them. We agree with the reviewer that this conclusion should not be based on positivity alone, but it isn't. The odds ratio allows us to consider both positivity/yield and volume. We have included a comments on statistical significance of the AOR for TB clinic on page 7, lines 220 and 221 of marked up version revised manuscript.

Background,page 4

Minor issue:

There is redundancy in the last few sentences of the last paragraph, suggest streamlining.

Authors' response:

The redundant sentences have been deleted, please see page 4, lines 95 to 97 of marked up version of revised manuscript

Methods

Study design, page 4

Minor issue:

Suggest adding retrospective to the design.

Authors' response:

We have updated study design as recommended. Please see page 4, lines 100 and 101 of marked up version of revised manuscript.

Study population, page 4

Minor issue:

Regional information missing. Rural, urban, semi-urban?

Authors' response:

The regional information on sites will not accurately define our population in this instance because the patients accessing care come from far and near to access services in the sites included for the study. Unfortunately, information on location of patients was not available for the analysis.

Outcomes measures, page 4

Major issues:

Incomplete, what about number and proportion tested and positive in each department?

For factors associated, give examples (i.e. testing acceptance)

Authors' response:

We have reorganized the section on outcome measures. The patient's factors included in the model for odds ratio were age group and HIV testing point of service. Please see page 4, lines 106 to 110 of marked up version of revised manuscript.

Description and process of site selection for pilot, page 4

Authors' response:

We described the process of site selection in detail. Please see page 4, lines 112 to 123 of marked up version of revised manuscript.

Minor issues:

Suggest starting with the first research activity done, for instance if the gap analysis was first, start there and flow forward to details of determining children ration.

Cite (220,000/3,400,000 estimated PLHIV)...

Authors' response:

We have reorganized the section based on reviewers recommendations. Please see page 4, lines 112 to 123 of marked up version of revised manuscript.

Strategies, page 4

Nice overall description of strategies and process to roll out.

Minor issues:

Consider adding when strategies were implemented to the first sentence

What department(s) was family testing conducted in?

Authors' response:

We have reorganized the section based on reviewers recommendations. We have added dates the strategies were implemented and described the departments that family index testing was implemented Please see page 5, lines 138 to 145 of marked up version of revised manuscript.

Data Analysis, page 5

Major issue

Section on data collection

In the Analysis section, suggest putting the sentence about STATA at the end

Authors' response:

We have reorganized the section based on reviewers recommendations. Please see page 6, lines 176 to 177 of the revised manuscript.

Results

Major issues -- editing and additional information

HIV Testing Outputs from all sites by POS by age group, page 6

Linkage mention seems out of place in this paragraph, consider its own paragraph and placing it with HIV testing cascade flow.

Authors' response:

In this section we described results presented on table 1 which included number of children initiated on ART. Therefore, the mention of linkage rate here was to ensure completeness of that information.

HIV Testing Outputs from all sites by POS, page 6

This text draws from Table 2, which is a nicely presented table of findings. The extra details on the family testing may not be essential here, so evident in the table and other departments are not presented similarly.

Authors' response:

In this study the family Index Testing was treated as a POS. We have included a detailed description of the family index testing modality in the method section. See excerpt included in section on strategies implemented during PICF pilot of marked up version of revised manuscript (page 5, lines 138 to 144)

Some redundancy of results mid-paragraph. Suggest refining and keeping any interpretation to

Authors' response:

We have refined section in line with authors comments.

Discussion.

Suggest that the results include a paragraph summarizes testing acceptance (based on Table 2), since it is discussed in the Discussion.

Authors' response:

We have included a paragraph summarizing the acceptance rates on page 7, lines 198 to 204 of the result section of marked up version of revised manuscript.

Discussion, page 7

Major issues - Some rewriting and reorganization is warranted:

Important points are captured here but suggested restructuring for better flow and presentation. For instance, first primary findings, then supporting / conflicting evidence, other findings, and limitations.

Authors' response:

We have reorganized the entire discussion session to improve flow.

Ordering suggestions

Paragraph 1 - Suggest starting with overall primary findings that answers research question

Authors' response:

We have started with paragraph that summarized findings from the study, please see page 8, lines 243 to 255 of marked up version of revised manuscript.

Paragraph 2 -- Suggest moving this further down since not about primary findings. Suggest adding references to support ideas here.

Authors' response:

We have included references to support our ideas and also reorganized the paragraph. The paragraph as been moved further down and its now the new paragraph 8. See page 9, lines 295 to 300

Paragraph 3 -- Suggest move this paragraph up since it supports primary findings. Any references to substantiate findings on inpatient care? For TB consider adding information to validate Conclusion statement.

Authors' response:

The paragraph has been moved up, its now the new paragraph 1 in revised manuscript.

Paragraph 4 -- Suggest keeping it after the above paragraph since tied to primary findings.

Authors' response:

We have maintained paragraph as suggested, please see page 8, lines 256 to 265

Paragraph 5 -- fine, no comments

Authors' response:

Okay

Paragraph 6 -- Systematic review on acceptance, interesting but need to mention acceptance in results Suggest starting with what the study found (to put it in context), then introduce the systematic review and corroborating findings

Authors' response:

We have included information on acceptance as requested in the results. Please see new paragraph summarizing the acceptance rates on page 10, lines 310 to 321 of the result section.

Paragraph 7 -- fine, no comments

Authors' response:

Okay

Paragraph 8 -- PEPFAR/inpatient ward-- suggest weaving into primary findings, since it is provides support for inpatient findings.

Authors' response:

Now integrated into a new paragraph 4 in the revised manuscript, please see page 4, lines 281 to 294 in the discussion section of the revised manuscript

Paragraph 9 -- fine, no comments

Conclusion

Question about this sentence: "Specifically, these modalities identified high numbers of children living with HIV while maintaining high yields"

isn't identifying high numbers of children living with HIV yield? Please clarify.

Authors' response:

We have effected change. The sentence now reads as follows: "Specifically, these modalities identified high numbers of children living with HIV while maintaining high HIV positivity rates"

Please see conclusion on page 12, lines 383 to 384 of marked up version of revised manuscript.

Reviewer 3 Comments and Authors' responses:

Title: In the title, what is the meaning of "high-yield facility based settings''? Did you mean " high-yield point of service?'' Somehow, the current title is not clear.

Authors' response:

Thank you for your comment. Authors agree with suggestions. The Title of the manuscripts now reads as follows: "Increasing pediatric HIV testing positivity rates through focused testing in high-yield point of service in health facilities---Nigeria, 2016-2017". Please review the title page of marked up version of revised manuscript. On page 1.

Abstract

1\. Reading the background, the problem you intend to solve is increasing pediatric ART in Nigeria. Thus, can you consider including the contribution of each POS to HIV seropositivity. This is important to show the contribution of POPD. Actually, though POPD has a lower yield, it has a meaningful contribution in case finding.

Authors' response:

We have now included the contributions of the various POS to the total HIV positive children found in the abstract of the revised manuscript. The following excerpt was included in abstract of revised manuscript: "The percentage contribution to total HIV positive children found by point of services was: Family index modality= 55.8% (95%CI: 40.9-69.8%); POPD=20.9% (95%CI: 11.3-35.6%); inpatient ward=20.9 (95%CI: 11.3-35.6%) and TB Clinic=2.3% (95%CI: 0.3-14.8%)."

Please see page 1, lines 38 to 40 of marked up version of revised manuscript.

2\. In the sentence "....group were 1-4 years =752 (41.3%); 10-14 years= 320 (17.6%);

5-9 years= 520 (28.5%); and \<1 years=230 (12.6%)'', the ordering of the age group is difficult to follow. I would order the age groups from the youngest to the oldest.

Authors' response:

We have now ordered age group by youngest to oldest. See excerpt included in abstract of revised manuscript: "The numbers of children tested by age group were \<1 years=230 (12.6%); 1-4 years =752 (41.3%); 5-9 years= 520 (28.5%); and 10-14 years= 320 (17.6%)."

Please see page 1, lines 31 to 33 of marked up version of revised manuscript.

3\. The conclusion does not tie with the results. TB clinic has the highest yield, therefore should come first in order of priority, follow by pediatric inpatient wards and family index testing.

Authors' response:

In this instance, the ordering in the conclusion was correct. Although TB clinic had the highest odds (TB clinic=7.2 (95% CI: 0.9-60.9)) for finding an HIV positive child. A careful examination of the confidence interval (CI) show a very wide CI starting from less than 1. This was because of the relative small number of HIV positive children identified at TB Clinic (2.3% of total positive children) compared with other POS. However, we have revised language to show the importance of family index texting. Please see page 1, lines 45 to 47 of marked up version of revised manuscript.

Introduction

General comments:

The problem statement (challenges in improving HIV case finding among children) and the efforts deploy by the Government of Nigeria (GON) and partners (notably PEPFAR) to address the issue is well described. However, there is no mentioned of the outcome implementation of the Nigeria National Acceleration Plan for Pediatric HIV treatment and Care, 2016-2018. This is the national document that introduced family index testing as a key strategy for pediatric HIV case finding in Nigeria. Thus, making reference to this Plan should further highlight the importance of the topic as well as the relevance/significance of your study. Dr. Uzoma Ene (co-author of this paper) was among the experts who elaborated this Acceleration Plan. I believe she can contribute in addressing this point.

Authors' response:

We have included a reference of the National Acceleration Plan for Pediatric HIV treatment and Care, 2016-2018 in the introduction. Please see page 1, lines 63 to 66 of marked up version of revised manuscript.

Specific comments:

Background:

Line 4-5: I would suggest updating the figure with current UNAIDS statistics (<https://www.unaids.org/en/regionscountries/countries/nigeria>)

i\) 220 000 is the upper limit of the CI. I would use but the point estimate which is 140 000 and indicate the CI= \[91 000 - 220 000\]

Authors' response:

The information earlier included were those available at the time of development of manuscript. We have now updated with current data. Please review lines 50 to 54 of the revised manuscript

ii\) 26% ART coverage is not current. Nigeria current ART coverage for children 0-14 is 35% \[22 - 53\].

Authors' response:

We have now updated with current data. Please review page 2, lines 50 to 56 of the marked-up version of the revised manuscript

iii\) References \[3\] and \[4\] are the same (<https://www.unaids.org/en/regionscountries/countries/nigeria>). Please, delete one.

Authors' response:

We have identified the duplicate reference and deleted as appropriate. Please review lines 50 to 54 of the marked-up version of the revised manuscript

Second to the last sentence of the 2nd paragraph:

Reference \#9: please update with 2018 data: ART coverage: males= 37%; females=68% \[<https://aidsinfo.unaids.org>\].

Authors' response:

We have now updated with current data. Please review lines 66 to 74 of the marked-up version of the revised manuscript

Last sentence of the 1st paragraph: ''Major reasons for the disproportionately lower coverage among children are lower HIV testing positivity rates, indicating poorly targeted testing, and lower linkage to treatment among children'': I think lower HIV testing positivity rate is just one of the reasons for the current low pediatric ART coverage. I would revise this sentence to indicate that major reasons for the disproportionately lower coverage among children include among others lower HIV testing positivity rates.

Authors' response:

Authors have revised sentence as recommended, please see page 3, lines 72 to 74 of the marked-up version of the revised manuscript

Methods

Strategies implemented during PICF pilot

P.4-Please describe how the index testing modality was implemented. Is it like outpatient parents diagnosed HIV positive were invited to bring their children for testing? or were index cases recruited among parents in HIV services in hospital (e.g: ART clinic or PMTCT)? A thorough description of the implementation of the index case testing is needed to understand the processes involved and how children were recruited for testing during the intervention period.

Authors' response:

We have included a detailed description of the family index testing modality in the method section. See excerpt included in section on strategies implemented during PICF pilot of the marked-up version of the revised manuscript (Please see page 5, lines 138 to 144): The family index modality identified new cases through a previously identified case, i.e. children of an HIV positive mother or siblings of an index child. HIV positive mothers were identified during posttest counselling, at the ART clinic, ante-natal clinic, post-natal clinic or outpatient clinics and encouraged to return to clinic with their children after counselling for a free HIV test. Additionally, parents of a previously identified HIV positive child were also encouraged to bring other children with unknown HIV status for an HIV test.

P.5-3rd sentence: ''Additionally, there was 100% index testing of children with HIV-positive mother or siblings'': This sentence is confusing when reading table 2 which indicates that 85.9% of children were successful tested through family index modality. How should we understand this difference? Moreover, does it mean only children of HIV-positive mothers were tested? How about fathers who tested positive in the hospital? Were they not also ask to bring their children for testing? If no, why? What was really the entry point for family index case testing? OPD, PMTCT, ART clinic?

Authors' response:

We have included a detailed description of the family index testing modality in the method section. See revised manuscript (lines122 to 127). The previously confusing sentence ''Additionally, there was 100% index testing of children with HIV-positive mother or siblings'' has been deleted. This pilot didn't not directly focus on fathers, because the majority of HIV children are infected by vertical transmission from an HIV positive mother to child. The entry points for family index has been described, please see lines 122 to 127.

P.5- ''These PICF strategies were piloted at the TB clinics, pediatric inpatient medical wards,

adult outpatient clinic among families of identified index cases, POPDs, and the immunization clinics in the selected sites'': where there ART and malnutrition clinics in the selected health facilities? if yes, why were they not included in the study knowing that these are high yield HIV case finding point of services?

Authors' response:

The clinics where the study was conducted were secondary level hospitals, the malnutrition clinics were not clearly defined. Most operated as part of the OPD. Furthermore, ART was not a testing stream for this study, only HIV positive children were seen at ART. However, the ART clinic served as a source for identifying children with siblings with unknown status that formed part of the family index testing modality.

Results

P.6. Last paragraph: Age and POS were the only predictors of seropositivity assessed (Table 3). Is it possible to assess more children-level socio-demographic factors such as sex, educational level among others?

Authors' response:

Unfortunately, we couldn't include other socio-demographic factors in the analysis model because they were not available. Our study is a secondary analysis of data obtained from a pilot. We are limited by available data.

Table 3: I think the title should read ''Unadjusted and adjusted odds ratios of pediatric HIV case detection by patient age group and POS\'\'

Authors' response:

Authors agree with reviewer's suggestions. We have made the suggested changes to table 3

Discussion

2nd sentence-1st paragraph: ''Several program strategies for improving efficiency of testing through increasing HIV positivity yield, while maintaining high numbers of HIV positive children found, and for improving efficacy of testing by assuring linkage to ART were implemented in selected health facilities providing HIV care''.\-\--� This sentence is too long and difficult to understand. What is the message here?

Authors' response:

This sentence have been deleted

2nd sentence-2nd paragraph: ''This may be because of a continued program emphasis on PMTCT: perhaps these youngest children were less likely to have unknown status or test positive because their mothers' status had been confirmed during pregnancy''\-\--� the explanation of the lowest proportion of children with unknown HIV status and tested HIV positive should be reviewed. Actually, youngest children were less likely to have unknown HIV status and test HIV positive not because '' their mothers' status had been confirmed during pregnancy'' , but more likely because these youngest children may have been tested for HIV and those tested HIV+ received ARV prophylaxis and this through the PMTCT program. This is suggestive of the effectiveness of PMTCT program in the selected health facilities.

Authors' response:

We have provided more clarification to the sentence in the revised manuscript. However, this paragraph have been moved down as requested by another reviewer. Please see page 11, lines 361 to 373 of the marked up version of the revised manuscript.

4th sentence-3rdparagraph: ''Even with the use of the HIV risk screening tool in the POPD, this POS gave a low yield of 1.0%''. \-\--� This is in my opinion a key finding of this paper considering the potential implications. Actually, the aim of the risk screening tool was to improve the yield. If this yield is still low at 1%, therefore the tool is not achieving the desired results. The reported yield in your study is even lower compared to the yield of the DHT (diagnostic HIV testing=symptoms-based testing strategy) among children reported at 4% in Cameroon (<https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0214251>). This suggests that compared to the Bandason screening tool, better yield can even be achieved focusing on testing only HIV symptomatic outpatient children. There is urgent need to re-assess the validity of the Bandason screening tool in low HIV prevalence context such as Nigeria.

Authors' response:

We agree with reviewers comment, we have included that perspective in the revised manuscript. Please lines 281 to 294 of the marked up version of the revised manuscript.

P.8: 1st sentence: ''Children for HIV testing (family index testing), found that the rate of pediatric case identification increased 3.8-fold from 3.5% to 13.6% \[15\]''\-\--� This statement is wrong because the reported figure correspond to the increase in HIV testing uptake and not case identification rate that was 7.4%. Please check your reference again.

Authors' response:

We have revised sentence to make it more explicit. Please see lines 256 to 259 of the marked up version of the revised manuscript.

3rd sentence: ''Our study results were comparable with findings in these studies''. \--�Which of your study results are you referring to? In your study, you did not compare the HIV testing uptake (before and after the intervention) instead you reported the family index case testing HIV positivity rate of 3.5% which is far different from the 7.4% reported by Wagner et al. in Kenya. Instead, your HIV positivity rate (3.5%) corresponds exactly to the 3.5% reported in the family index case testing study in the neighbouring Cameroon by Yumo et al. (see reference\#10 of your manuscript).

Authors' response:

We have provided a clearer description in the revised manuscript. Please see lines 266 to 273 of the marked up version of the revised manuscript.

2nd sentence-3rd paragraph: ''With exception of the immunization clinic, our study found a

much higher acceptance rate among all the provider-initiated testing and counseling POS in our study sites, which may indicate that the pre-test counseling being done for families of at-risk pediatric patients at these sites is effective''\-\--� You may support your findings with evidence from neighbouring Cameroon equally showing higher acceptance (99.7%) among parents (Yumo et al.=\> see ref 10) and Ida Penda et al( .<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090739/>).

Authors' response:

We have included additional comparison with studies from Yumo et al. Please see lines 310 to 321 of revised manuscript.

2nd sentence- 4th paragraph: ''About 24% of children with unknown status identified through the family index POS were not tested for HIV''\-\-\--�This is about 2 times less than the 44% reported by Yumo et al. in Cameroon (see reference 10 of your manuscript). Can you explain this better outcome?

Authors' response:

We will not be able to explain the differences in outcomes in the two studies. However, we have compared findings in both studies to enable readers have both perspective. Please review description in lines 335 to 344 of the marked up version of the revised manuscript.

4th sentence-4th paragraph: ''Our study did not investigate the reasons for the failure of parents or guardians to return with their children''.\-\--�These reasons were investigated by Yumo et al. in a similar study in Cameroon (see reasons in ref. above).

Authors' response:

We have reviewed reports from Yumo et al, their insinuation was similar with what was already described in our manuscript. Please review description in lines 335 to 351 of the marked up version of the revised manuscript.

2nd sentence-5th paragraph: ''Our findings that pediatric inpatient ward was an efficient POS for finding children living with HIV while maintaining a yield higher than the overall yield corroborates that guidance''\--�However, the contribution of inpatient (20.9%) to case finding load is similar to POPD (20.9%) and far lower to family index testing modality (55.8%). Thus, there is need for the combination of these POS, even if it means somehow losing in efficiency at the POPD. This finding simply shows the challenge in achieving optimal coverage while maintaining efficiency.

Authors' response:

We agree with reviewers comment. Actually our follow on sentence in same paragraph (lines 307 to 312) makes that point exactly. Although, the contribution of inpatient (20.9%) to case finding load was similar to POPD (20.9%), a lot more test was done at POPD to find the same number of patients. Our recommendation to use risk stratification will ensure programs test the most at risk population and improve testing efficiency at POPD.

3rd sentence-5th paragraph: '' We found that the family index testing modality was the most efficient POS for all sites, accounting for about 38% of total children tested but contributing more than half (55.8%) of all the positives identified''\--�This was the key strategy outlined in the National Acceleration Plan for Pediatric HIV Treatment and Care for Nigeria (Please, see Dr Uzoma Ene for reference). This finding indicates that if implemented at scale, this Plan could help in bridging the current gap in pediatric ART in Nigeria.

Authors' response:

We agree with reviewers comment. We have made that point in the revised manuscript. Please see page 9, lines 281 to 294, in discussion of marked up version of revised manuscript.

3rd sentence-5th paragraph: ''While we found a low yield in the POPD, because so many children seek care there in Nigeria, testing there may still represent a way to find more children living with HIV''-� This is correct, but contradicts a little bit your statement above re prioritizing inpatients testing.

Authors' response:

We have rephrased sentence to make it clearer. Please see lines 291 to 294 under discussion in the revised manuscript.

4th sentence-5th paragraph: '' However, in order for this to be efficient, there needs to be a program emphasis on fidelity to the HIV risk stratification tool''-� This sentence is not clear. Are you referring here to the need of using a screening tool? if yes, as indicated above, please refer to comment above re the use of the Bandason screening tool in Nigeria.

Authors' response:

We have rephrased sentence to make it clearer. Please see page 9, lines 291 to 294 under discussion in the revised manuscript.

2nd sentence-6th paragraph: ''However, the purposive nature of site selection limits the generability of the findings from our analysis''-� Other high yield POS such ART clinics (for index case testing) and malnutrition clinics were not explored. This is another limitation of the study because information from these POS could have given more beef to the paper.

Authors' response:

The ART clinic was one of the places used to elicit index for testing. Please refer to lines 138 to 144 of the revised manuscript. However, we have included our inability to thoroughly explore malnutrition clinics as a limitation. Please see lines 374 to 379 under discussion in the revised manuscript.

Conclusion

3rd sentence: ''The study findings suggested that to improve facility-based HIV positivity rates

among children aged 0--14 years in Nigeria, an increased focus on HIV testing among children seeking care in pediatric inpatient wards, through family index testing, and perhaps in TB clinics is appropriate'-� in this sentence, I would remove \'\'perhaps\'\', include the POPD as another priority testing point while recommending the re-assessment of the validity of the Bandason tool in low HIV prevalence context such as Nigeria. We can\'t afford not to test children at the OPD as it's an important POS considering it contribution in pediatric HIV case finding load.

Authors' response:

We have rephrased the conclusion in line with suggestions from reviewer. Please see lines 370 to 379 in revised manuscript. We have also made the point for the need to re-assess the validity of the Bandason tool in low HIV prevalence context such as Nigeria in lines 279 to 287 of revised manuscript. However, we could not remove the word 'perhaps' from our description for TB clinic becaue our study was not sufficiently powered to give an accurate inference for testing in the TB clinic.

Others: The review of this paper was made unmercenary difficult because the lines are not numbered. Please, kindly numbered the lines in the revised version before re-submission.

Authors' response:

Manuscript text are now numbered.
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